New York: Remdesivir, an antiviral drug initially developed to treat Ebola by the pharmaceutical company Gilead, has “little or no effect” on survival for people in hospital with COVID-19, a World Health Organization (WHO) trial has found. As part of its SOLIDARITY trial, WHO researchers tested the effects of four potential treatments, including antiviral drugs remdesivir and interferon-β1a, the … Continue reading Remdesivir provides little effect on COVID-19: WHO